Sitravatinib (CHEM132749)
| Record Information | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Version | 1.0 | ||||||||
| Creation Date | 2026-04-14 20:04:06 UTC | ||||||||
| Update Date | 2026-08-22 11:06:50 UTC | ||||||||
| Accession Number | CHEM132749 | ||||||||
| Identification | |||||||||
| Common Name | Sitravatinib | ||||||||
| Class | Small Molecule | ||||||||
| Description | Sitravatinib is an organic compound with the chemical formula C33H29F2N5O4S. Sitravatinib belongs to the ethers, a subclass of organooxygen compounds within the organic compounds. With an average molecular weight of 629.68 g/mol, Sitravatinib is a heavy molecule. In terms of biological activity, Sitravatinib functions as an inhibitor of four recorded protein targets. These include the Hepatocyte growth factor receptor (MET), the Vascular endothelial growth factor receptor 2 (KDR), and the Vascular endothelial growth factor receptor 3 (FLT4). Additionally, it acts as an inhibitor of the Proto-oncogene tyrosine-protein kinase receptor Ret (RET). | ||||||||
| Contaminant Sources | Not Available | ||||||||
| Contaminant Type | Not Available | ||||||||
| Chemical Structure |  | ||||||||
| Synonyms | Not Available | ||||||||
| Chemical Formula | C33H29F2N5O4S | ||||||||
| Average Molecular Mass | 629.680 g/mol | ||||||||
| Monoisotopic Mass | 629.191 g/mol | ||||||||
| CAS Registry Number | 1123837-84-2 | ||||||||
| IUPAC Name | N'1-(3-fluoro-4-{[2-(5-{[(2-methoxyethyl)amino]methyl}pyridin-2-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | ||||||||
| Traditional Name | Not Available | ||||||||
| SMILES | COCCNCC1=CC=C(N=C1)C1=CC2=C(S1)C(OC1=C(F)C=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2 | ||||||||
| InChI Identifier | InChI=1S/C33H29F2N5O4S/c1-43-15-14-36-18-20-2-8-25(38-19-20)29-17-26-30(45-29)28(10-13-37-26)44-27-9-7-23(16-24(27)35)40-32(42)33(11-12-33)31(41)39-22-5-3-21(34)4-6-22/h2-10,13,16-17,19,36H,11-12,14-15,18H2,1H3,(H,39,41)(H,40,42) | ||||||||
| InChI Key | WLAVZAAODLTUSW-UHFFFAOYSA-N | ||||||||
| Chemical Taxonomy | |||||||||
| Classification | Not classified | ||||||||
| Biological Properties | |||||||||
| Status | Detected and Not Quantified | ||||||||
| Origin | Not Available | ||||||||
| Cellular Locations | Not Available | ||||||||
| Biofluid Locations | Not Available | ||||||||
| Tissue Locations | Not Available | ||||||||
| Pathways | Not Available | ||||||||
| Applications | Not Available | ||||||||
| Biological Roles | Not Available | ||||||||
| Chemical Roles | Not Available | ||||||||
| Physical Properties | |||||||||
| State | Not Available | ||||||||
| Appearance | Not Available | ||||||||
| Experimental Properties |
| ||||||||
| Predicted Properties | Not Available | ||||||||
| Spectra | |||||||||
| Spectra |
| ||||||||
| Toxicity Profile | |||||||||
| Route of Exposure | Not Available | ||||||||
| Mechanism of Toxicity | Not Available | ||||||||
| Metabolism | Not Available | ||||||||
| Toxicity Values | Not Available | ||||||||
| Lethal Dose | Not Available | ||||||||
| Carcinogenicity (IARC Classification) | Not Available | ||||||||
| Uses/Sources | Not Available | ||||||||
| Minimum Risk Level | Not Available | ||||||||
| Health Effects | Not Available | ||||||||
| Symptoms | Not Available | ||||||||
| Treatment | Not Available | ||||||||
| Concentrations | |||||||||
| Not Available | |||||||||
| External Links | |||||||||
| Identifiers | Not Available | ||||||||
| References | |||||||||
| Synthesis Reference | Not Available | ||||||||
| MSDS | Not Available | ||||||||
| General References | Not Available | ||||||||
